| Lian Chen,Ling Wu,Zhang Lu,Qin Huang,Liu Huang. Treatment-related adverse events of combined anti-angiogenic and immune checkpoint inhibitors: systematic review and meta-analysis. Oncol Transl Med, 2022, 8: 301-310. |
| 抗血管联合免疫检查点抑制剂的治疗相关副作用：系统性回顾和荟萃分析 |
| Treatment-related adverse events of combined anti-angiogenic and immune checkpoint inhibitors: systematic review and meta-analysis |
| Received:October 28, 2022 Revised:October 28, 2022 |
| DOI：10.1007/s10330-022-0605-5 |
| 中文关键词: 联合治疗, 免疫检查点抑制剂, 抗血管抑制剂, 治疗相关副作用, 系统性回顾, 荟萃分析 |
| 英文关键词: combination therapy, immune checkpoint inhibitor, angiogenesis inhibitor, treatment-related adverse events, systematic review, meta-analysis |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Lian Chen | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | 6212809071@stu.jiangnan.edu.cn | | Ling Wu | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China | | | Zhang Lu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China | | | Qin Huang | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China | | | Liu Huang* | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China | |
|
| Hits: 3641 |
| Download times: 4527 |
| 中文摘要: |
| 摘要
背景: 免疫联合抗血管治疗多种癌种中是一种新型的治疗模式，其通过使肿瘤血管正常化以增强肿瘤免疫。在这篇回顾性文章中，我们总结已报导的临床相关的研究中免疫联合抗血管治疗相关不良反应和所有的致命性的案例。
方法: 从4个数据库中系统性的查找了符合条件的文献，最终挑出符合要求的文献有28篇。
结果: 58.1%的病人发生了3级不良反应。最常见的致命性不良反应有心血管反应，重度感染和出血。对比抗血管单药治疗，免疫联合抗血管会发生更多的3级及以上蛋白尿，肝损伤和和致命性不良反应，尤其是呼吸系统, 毒性反应和重度感染。但是免疫联合抗血管减少了血液系统的毒性反应。
结论: 我们分享了全面的，真实的免疫联合抗血管治疗安全性的信息。 |
| 英文摘要: |
| Objective Immune checkpoint inhibitor (ICI) plus angiogenesis inhibitor (AI) combination therapy is a
novel treatment model for multiple cancers that normalizes vascular-immune crosstalk to potentiate cancer
immunity. In this review, we summarize the characteristics of adverse effects (AEs) and all fatal cases
reported in clinical studies involing ICI + AI therapy.
Methods Four databases were systematically searched for eligible studies, and 28 relevant studies were
selected for inclusion.
Results Of the patients included, 58.1% developed grade ≥ 3 AEs. The most common fatal AEs were
cardiovascular events, severe infections, and hemorrhage. Compared with AI alone, ICI + AI therapy
resulted in more cases of grade ≥ 3 proteinuria, liver injury, and fatal AEs (2.49% vs. 1.28%, P = 0.0041),
especially respiratory toxicities and severe infections; however, ICI + AI therapy reduced hematological
toxicity.
Conclusion We shared comprehensive and practical safety data to review the adverse events associated
with ICI + AI treatment. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|